Ajanta Pharma Reports 18.4% Increase in Q4 FY26 Net Profit
Ajanta Pharma Q4 FY26 results: Net profit rises 18.4% to ₹266.7 crore
Business Standard
Image: Business Standard
Ajanta Pharma Ltd reported an 18.4% increase in consolidated net profit to ₹266.7 crore for Q4 FY26, driven by strong growth in US generics. The company's total revenue for the quarter reached ₹1,421.64 crore, reflecting significant gains in both domestic and international markets.
- 01Net profit rose to ₹266.7 crore in Q4 FY26, up 18.4% from the previous year.
- 02Total revenue for Q4 FY26 reached ₹1,421.64 crore, a significant increase from ₹1,170.41 crore.
- 03US generics revenue surged by 56% to ₹505 crore.
- 04Branded generics revenue in India, Asia, and Africa grew by 7% to ₹859 crore.
- 05For FY26, consolidated net profit was ₹1,056 crore, up from ₹920.39 crore in FY25.
Advertisement
In-Article Ad
Ajanta Pharma Ltd, a pharmaceutical company based in India, reported a consolidated net profit of ₹266.7 crore for the fourth quarter ending March 31, FY26, marking an 18.4% increase from ₹225.26 crore in the same quarter last year. The company's consolidated revenue from operations for the quarter was ₹1,421.64 crore, up from ₹1,170.41 crore in the previous year, driven primarily by robust sales in the US generics market. US generics revenue soared by 56%, reaching ₹505 crore, while branded generics in India, Asia, and Africa contributed ₹859 crore, a 7% increase from the prior year. For the entire fiscal year FY26, Ajanta Pharma's consolidated net profit stood at ₹1,056 crore, compared to ₹920.39 crore in FY25, with total revenue from operations at ₹5,452.86 crore, up from ₹4,648.1 crore in the previous fiscal year.
Advertisement
In-Article Ad
The growth in Ajanta Pharma's profits indicates a positive trend in the pharmaceutical sector, which could lead to increased investments and job creation in the industry.
Advertisement
In-Article Ad
Reader Poll
Do you think Ajanta Pharma will continue to grow in the next fiscal year?
Connecting to poll...
Read the original article
Visit the source for the complete story.